Despite safe and effective vaccines being available for a wide range of infectious diseases, prevention and treatment of more complex conditions, including allergy and cancer, remain elusive. Furthermore, vaccines are complex to manufacture, making them difficult to produce to a scale, quality and cost that supports widespread global access. An ongoing collaboration between South Australian biotech company Sementis Ltd and UniSA’s Experimental Therapeutics Laboratory has developed a vaccine delivery platform that can potentially produce easy-to-manufacture vaccines for multiple acute and chronic disease conditions.
Leverage our expertise to find research funding support
